Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 13/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664723 | 0.92 | GCK (0.51) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL14546873 | 0.89 | FFAR2 (0.40) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL1797368 | 0.86 | GCK (0.40) | GCKRARARARBRARG | |
| SCHEMBL13888268 | 0.86 | SMN1; SMN2 (0.50) | GCKCSNK2A2CSNK2A1 | |
| SCHEMBL2664722 | 0.85 | GCK (0.63) | GCKRARARARBRARG | |
| SCHEMBL12616501 | 0.85 | GCK (0.51) | GCKRARARARBRARG | |
| SCHEMBL2664562 | 0.85 | GCK (0.46) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL2664568 | 0.85 | GCK (0.46) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL2664710 | 0.85 | GCK (0.43) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL2664761 | 0.84 | GCK (0.50) | GCKRARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| EP-1529530-B3 | Compounds affecting glucokinase | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1568367-B3 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| EP-1661569-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661563-A1 | Compound effecting Glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661567-A1 | Compounds effecting Glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1420784-B1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1568367-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1529530-A1 | Compounds affecting glucokinase | AstraZeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20050080106-A1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2005-04-14 | — | — | US | disclosed |
| EP-1420784-A1 | COMPOUNDS EFFECTING GLUCOKINASE | Astrazeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003015774-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003015774-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080106-A1 | Compounds effecting glucokinase | GCKR, GCK, SLC5A2 | GCK 2/4885RARA 3925/4885RARB 3902/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | GCK 2/4885RARA 3925/4885RARB 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.